08.19.15
Results from the interim analysis of the Compass study are now available. The study, which is assessing the safety and effectiveness of the epidural space verification with the Compuflo epidural computer controlled system, was initiated in February.
The Compuflo system is a computer-controlled drug delivery injection system that incorporates Dynamic Pressure Sensing technology for safer and painless delivery (and fluid aspiration) of all medicaments. The technology belongs to Livingston, N.J.-based Milestone Scientific Inc.
Milestone Scientific’s epidural and intra-articular (IA) subsidiary also reported that the clinical trial for the epidural instrument has reached an enrollment of 200 patients.
"The interim analysis of the Compass study clearly achieved the goal set by the U.S. Food and Drug Administration Investigational Device Exemption Investigational Plan,” said CEO of Milestone Scientific Leonard Osser. “We look forward to expeditiously continuing our enrollment and completing our trial later this year. With the U.S. epidural market estimated at over $7 billion annually and over 2.4 million women receiving epidurals, we believe this instrument will help reduce health risks to patients and malpractice risk to medical professionals administering epidurals.”
Milestone Scientific is a medical research and development company that designs, patents, incubates and commercializes a portfolio of injection technologies.
The Compuflo system is a computer-controlled drug delivery injection system that incorporates Dynamic Pressure Sensing technology for safer and painless delivery (and fluid aspiration) of all medicaments. The technology belongs to Livingston, N.J.-based Milestone Scientific Inc.
Milestone Scientific’s epidural and intra-articular (IA) subsidiary also reported that the clinical trial for the epidural instrument has reached an enrollment of 200 patients.
"The interim analysis of the Compass study clearly achieved the goal set by the U.S. Food and Drug Administration Investigational Device Exemption Investigational Plan,” said CEO of Milestone Scientific Leonard Osser. “We look forward to expeditiously continuing our enrollment and completing our trial later this year. With the U.S. epidural market estimated at over $7 billion annually and over 2.4 million women receiving epidurals, we believe this instrument will help reduce health risks to patients and malpractice risk to medical professionals administering epidurals.”
Milestone Scientific is a medical research and development company that designs, patents, incubates and commercializes a portfolio of injection technologies.